A retrospective study comparing postoperative outcomes of vedolizumab and anti-TNF therapy in pediatric patients undergoing abdominal operations for inflammatory bowel disease
Latest Information Update: 07 Dec 2018
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- 07 Dec 2018 New trial record